Intrahepatic Cholangiocarcinoma  >>  Stivarga (regorafenib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stivarga (regorafenib) / Bayer
NCT02053376: A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

Completed
2
43
US
Regorafenib, STIVARGA
Nathan Bahary, MD, Bayer
Metastatic Biliary Tract Carcinoma
01/18
05/18

Download Options